AU2022325958A1 - Novel omni 115, 124, 127, 144-149, 159, 218, 237, 248, 251-253 and 259 crispr nucleases - Google Patents
Novel omni 115, 124, 127, 144-149, 159, 218, 237, 248, 251-253 and 259 crispr nucleases Download PDFInfo
- Publication number
- AU2022325958A1 AU2022325958A1 AU2022325958A AU2022325958A AU2022325958A1 AU 2022325958 A1 AU2022325958 A1 AU 2022325958A1 AU 2022325958 A AU2022325958 A AU 2022325958A AU 2022325958 A AU2022325958 A AU 2022325958A AU 2022325958 A1 AU2022325958 A1 AU 2022325958A1
- Authority
- AU
- Australia
- Prior art keywords
- sequence
- seq
- rna
- molecule
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163232723P | 2021-08-13 | 2021-08-13 | |
| US63/232,723 | 2021-08-13 | ||
| PCT/US2022/074941 WO2023019269A2 (en) | 2021-08-13 | 2022-08-12 | Novel omni 115, 124, 127, 144-149, 159, 218, 237, 248, 251-253 and 259 crispr nucleases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022325958A1 true AU2022325958A1 (en) | 2024-03-21 |
Family
ID=85201029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022325958A Pending AU2022325958A1 (en) | 2021-08-13 | 2022-08-12 | Novel omni 115, 124, 127, 144-149, 159, 218, 237, 248, 251-253 and 259 crispr nucleases |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240376453A1 (https=) |
| EP (1) | EP4384610A4 (https=) |
| JP (1) | JP2024532784A (https=) |
| KR (1) | KR20240045285A (https=) |
| CN (1) | CN118103503A (https=) |
| AU (1) | AU2022325958A1 (https=) |
| CA (1) | CA3228373A1 (https=) |
| IL (1) | IL310732A (https=) |
| WO (1) | WO2023019269A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024506608A (ja) | 2021-02-08 | 2024-02-14 | エメンドバイオ・インコーポレイテッド | Ｏｍｎｉ－１０３ ｃｒｉｓｐｒヌクレアーゼ |
| US12091688B2 (en) | 2021-02-08 | 2024-09-17 | Emendobio Inc. | OMNI-103 CRISPR nuclease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018081728A1 (en) * | 2016-10-31 | 2018-05-03 | Emendobio Inc. | Compositions for genome editing |
| SG11201906297QA (en) * | 2017-03-24 | 2019-10-30 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
| WO2019165168A1 (en) * | 2018-02-23 | 2019-08-29 | Pioneer Hi-Bred International, Inc. | Novel cas9 orthologs |
| US20220213456A1 (en) * | 2019-04-30 | 2022-07-07 | Emendobio Inc. | Novel omni crispr nucleases |
| WO2021097271A1 (en) * | 2019-11-15 | 2021-05-20 | Assembly Biosciences, Inc. | Compositions comprising bacterial species and methods related thereto |
| EP4259159A4 (en) * | 2020-12-14 | 2025-04-09 | Emendobio Inc. | Biallelic knockout of trac |
| WO2022132765A1 (en) * | 2020-12-14 | 2022-06-23 | Emendobio Inc. | Biallelic knockout of b2m |
-
2022
- 2022-08-12 IL IL310732A patent/IL310732A/en unknown
- 2022-08-12 CA CA3228373A patent/CA3228373A1/en active Pending
- 2022-08-12 CN CN202280068825.XA patent/CN118103503A/zh active Pending
- 2022-08-12 KR KR1020247008131A patent/KR20240045285A/ko active Pending
- 2022-08-12 WO PCT/US2022/074941 patent/WO2023019269A2/en not_active Ceased
- 2022-08-12 EP EP22856851.5A patent/EP4384610A4/en active Pending
- 2022-08-12 US US18/683,113 patent/US20240376453A1/en active Pending
- 2022-08-12 JP JP2024508548A patent/JP2024532784A/ja active Pending
- 2022-08-12 AU AU2022325958A patent/AU2022325958A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3228373A1 (en) | 2023-02-16 |
| KR20240045285A (ko) | 2024-04-05 |
| WO2023019269A2 (en) | 2023-02-16 |
| WO2023019269A3 (en) | 2023-04-13 |
| IL310732A (en) | 2024-04-01 |
| JP2024532784A (ja) | 2024-09-10 |
| US20240376453A1 (en) | 2024-11-14 |
| EP4384610A2 (en) | 2024-06-19 |
| CN118103503A (zh) | 2024-05-28 |
| EP4384610A4 (en) | 2025-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024050582A (ja) | 新規のｏｍｎｉ－５０ｃｒｉｓｐｒヌクレアーゼ | |
| WO2020223553A9 (en) | Novel omni crispr nucleases | |
| WO2021248016A2 (en) | Novel omni-59, 61, 67, 76, 79, 80, 81, and 82 crispr nucleases | |
| KR20240135610A (ko) | Omni-103 crispr 뉴클레아제-rna 복합체 | |
| WO2022170216A2 (en) | Omni 90-99, 101, 104-110, 114, 116, 118-123, 125, 126, 128, 129, and 131-138 crispr nucleases | |
| WO2022226215A1 (en) | NOVEL OMNI 117, 140, 150-158, 160-165, 167-177, 180-188, 191-198, 200, 201, 203, 205-209, 211-217, 219, 220, 222, 223, 226, 227, 229, 231-236, 238-245, 247, 250, 254, 256, 257, 260 and 262 CRISPR NUCLEASES | |
| EP4240848A1 (en) | Novel omni-50 crispr nuclease-rna complexes | |
| AU2022325958A1 (en) | Novel omni 115, 124, 127, 144-149, 159, 218, 237, 248, 251-253 and 259 crispr nucleases | |
| WO2023091987A2 (en) | Omni 263, 264, 266, 268, 269, 271, 274, 275, 276, 278, 279, 280, 281, 283, 284, 286,287, 288, 290, 291, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 307,308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325,326, 327, 329, 330, 331, 332, 333, 334, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345,346, 347, 348, 349, 350, 351, 352, 353, 354, 356, 357, 358, 359, 360, 361, 362, 363, 364,365, 366, 367, 368, 369, 370, 371, 372, 373, 375, 376, 377, 378, 380, 381, 382, 383, 384, 385, and 386 crispr nucleases | |
| WO2022170199A2 (en) | Omni-103 crispr nuclease | |
| EP4232573A1 (en) | Novel omni 56, 58, 65, 68, 71, 75, 78, and 84 crispr nucleases | |
| WO2024148061A2 (en) | Omni xl 1-22 crispr nucleases | |
| EP4642907A2 (en) | Omni-335 crispr nuclease | |
| HK40111655A (zh) | 新型omni 115、124、127、144-149、159、218、237、248、251-253和259 crispr核酸酶 | |
| CN117597142A (zh) | Omni 90-99、101、104-110、114、116、118-123、125、126、128、129和131-138 crispr核酸酶 |